AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.
You may also be interested in...
But because of the remaining uncertainty in the clinical evidence for this "potentially curative treatment," – Imfinzi for Stage III NSCLC – UK reimbursement will come from the Cancer Drugs Fund until more data accrues from the PACIFIC study, due to report in 2021.
AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.